key: cord-0752940-5b7vutw9
authors: May, Michael; Chang, Michelle; Dietz, Donald; Shoucri, Sherif; Laracy, Justin; Sobieszczyk, Magdalena E.; Uhlemann, Anne-Catrin; Zucker, Jason; Kubin, Christine J.
title: Limited Utility of Procalcitonin in Identifying Community-Associated Bacterial Infections in Patients Presenting with Coronavirus Disease 2019
date: 2021-03-18
journal: Antimicrob Agents Chemother
DOI: 10.1128/aac.02167-20
sha: 64393bf4669b3e64638fd54f4299de226a3bf483
doc_id: 752940
cord_uid: 5b7vutw9

The role of procalcitonin in identifying community-associated bacterial infections among patients with coronavirus disease 2019 is not yet established. In 2,443 patients of whom 148 had bacterial coinfections, mean procalcitonin levels were significantly higher with any bacterial infection (13.16 ± 51.19 ng/ml; P = 0.0091) and with bacteremia (34.25 ± 85.01 ng/ml; P = 0.0125) than without infection (2.00 ± 15.26 ng/ml). Procalcitonin (cutoff, 0.25 or 0.50 ng/ml) did not reliably identify bacterial coinfections but may be useful in excluding bacterial infection.

abscess fluid (3), pericardial fluid (3), wounds (1), lung tissue (1) , or other soft tissue (3) within 72 h of presentation. We also excluded patients in whom procalcitonin was not measured within 72 h of presentation. This study was approved by the Columbia University Institutional Review Board with a waiver for informed consent.

We obtained data from the NYP/CUIMC Clinical Data Warehouse, which contains electronic data for inpatient and outpatient visits, including demographics, diagnoses, laboratory tests, and other clinical variables. Diagnoses were extracted from inpatient and outpatient records by searching for diagnosis codes from the International Classification of Diseases, 9th and 10th editions. Data extracted included demographics, labs on first presentation with a positive SARS-CoV-2 RT-PCR, comorbidities, and microbiological results. Of note, our institutional protocol for the care of patients with COVID-19 recommends immediate measurement of procalcitonin, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), IL-6, and D-dimer, followed by repeat measurements every 72 h. Thus, the procalcitonin values measured in our study reflect values that were drawn from patients in the ED or shortly after, and we excluded values drawn .72 h after presentation.

We divided patients into those with community-associated bacteremia, bacterial pneumonia, and bacteriuria, as defined by positive microbiological results from the corresponding site, and those without CAI (control). This control group included patients with no positive microbiological results and those who developed bacterial infections .72 h into their admission. We excluded patients with a positive urine culture but an associated urinalysis with ,10 white blood cells from our analyses. We evaluated the mean, median, and standard deviation of initial procalcitonin values in these groups. We compared the distribution of initial procalcitonin values in the groups with CAI with those in patients without CAI using a 2-sided t test. P values of ,0.05 were considered significant.

We performed analyses on the utility of procalcitonin cutoff values of 0.25 and 0.5 ng/ml to identify the presence of CAI, values studied in the PRORATA and ProHOSP trials (8, 15) . These analyses included sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). We used Student's t tests to evaluate significant differences in mean procalcitonin values between groups.

We evaluated 2,443 patients who presented to the ED with COVID-19 during the study period and met inclusion criteria. Of these patients, community-associated bacteriuria, bacteremia, and bacterial pneumonia were identified in 88, 47, and 24 patients, respectively. Only 148 patients accounted for the 159 infections due to the presence of bacterial infections from multiple sources in a small subset of patients. Prevalence of bacterial infection was 6.1%. Subgroup demographics are presented in Table 1 .

Of patients with positive urine cultures, the most common genera were Escherichia (59%), Klebsiella (10%), Enterococcus (8%), and Proteus (8%). Of those with bloodstream infections, the most common genera were Streptococcus (21%), Staphylococcus (15%), Escherichia (17%), and Klebsiella (11%). Of patients with staphylococcal bacteremia, 14% (n = 1) had Staphylococcus epidermidis and 86% Staphylococcus aureus infections. Of patients with bacterial pneumonia, the most common genera were Staphylococcus (50%) and Pseudomonas (25%).

Mean procalcitonin levels were significantly higher in patients with any CAI than in those without CAI (13.16 versus 2.00 ng/ml; P = 0.0091). This was driven by patients with bloodstream infections (34.25 ng/ml) more than those with bacteriuria (5.15 ng/ml) or bacterial pneumonia (16.42 ng/ml) ( Table 1) . A procalcitonin cutoff of 0.25 ng/ml had a sensitivity of 0.568, 0.681, and 0.708; a specificity of 0.527, 0.528, and 0.526; a PPV of 0.043, 0.027, and 0.015; and an NPV of 0.970, 0.988, and 0.995 for detection of community-associated bacteriuria, bacteremia, and bacterial pneumonia, respectively (Tables 2 and 3) . Using a procalcitonin level of 0.50 did not significantly change these values (Table 2) .

Among other compared inflammatory markers, ferritin and ESR did not differ significantly between groups. Mean IL-6 levels were significantly higher in patients with bacterial pneumonia (81 pg/ml; P = 0.028) and bacteremia (67 pg/ml; P = 0.020) than in patients without CAI (40 pg/ml). Mean CRP was also higher in patients with bacterial pneumonia (162 mg/liter; P = 0.241) and bacteremia (170 mg/liter; P = 0.031) than in those without CAI (133 mg/liter) ( Table 1) .

This analysis showed that procalcitonin was a poor predictor of CAI among adult patients with COVID-19. Whereas procalcitonin was significantly elevated in patients with CAI compared with uninfected individuals, it demonstrated low sensitivity and specificity for identifying community-associated bacteremia, bacterial pneumonia, and bacteriuria, using a cutoff of 0.25 or 0.5 ng/ml. Although procalcitonin demonstrated an excellent NPV for ruling out CAI, this was likely driven by the low prevalence of CAI. Our findings suggest that elevated procalcitonin in COVID-19 is primarily driven by the inflammation caused by the disease itself rather than by bacterial coinfection. Based on our results, it appears that procalcitonin is not a reliable guide for the decision to initiate antibiotics in patients with COVID-19. Furthermore, the low rate of CAI argues against widespread empirical use of antibiotics in this population.

Strengths of this study include its large number of subjects (2, 443) . Limitations include our definition of bacterial infection solely as a positive microbiological result without accounting for clinical features. Underestimation of the infection rate is possible if a significant number of patients in our study had bacterial pneumonias, but respiratory cultures were not sent or were negative. Some of our culture results may also represent contaminants rather than true infections. Reassuringly, only one positive blood culture was a coagulase-negative Staphylococcus species. Although some small studies have been conducted regarding the utility of procalcitonin in urinary tract infections, data are not definitive in this setting (16) . Finally, a potential source of bias in this study is the possibility that elevated procalcitonin may have influenced the decision to send cultures.

Our findings indicate that in patients with COVID-19, procalcitonin does not succeed in identifying CAI, although it may have utility in ruling out infection and limiting antibiotic use. Further investigation regarding the role of procalcitonin in patients with COVID-19 is necessary.

We acknowledge use of data in the COVID-CARE database based at NYP/CUIMC, Division of Infectious Diseases. This work was supported by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) (grants 5UM1AI069470-14 and supplement to M.E.S., K23AI150378 to J.Z., and L30AI133789 to J.Z.). J.L. was supported by NIH NIAID award number T32AI114398.

The content is solely the responsibility of the authors and does not necessarily represent the official views of NIH. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication. 

Procalcitonin as a biomarker in respiratory tract infection

Procalcitonin as a marker of etiology in adults hospitalized with community-acquired pneumonia

Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis

Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations

Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis

In vitro and in vivo calcitonin I gene expression in parenchymal cells: a novel product of human adipose tissue

Procalcitonin-guided antibiotic treatment in patients with positive blood cultures: a patient-level metaanalysis of randomized trials

Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial

Early predictors of clinical deterioration in a cohort of 239 patients hospitalized for Covid-19 infection in Lombardy

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

China Medical Treatment Expert Group for Covid-19. 2020. Clinical characteristics of coronavirus disease 2019 in China

Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Risk factors of severe disease and efficacy of treatment in patients infected with COVID-19: a systematic review, meta-analysis and meta-regression analysis

Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial

Utility of initial procalcitonin values to predict urinary tract infection